Pharmaceuticals, Biotechnology and Life Sciences
China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world’s second-largest drug market where many new drugs have been kept out of patients’ reach because of high costs.
Shire will now be able to use its Adynovate for treating heamophilia A in children younger than 12 years of age, as the the U.S. Food and Drug Administration (FDA) has approved it for that age group. The FDA has also…
Shire doubles third quarter revenues, operates with net loss in Q3
Shire’s antiviral agent maribavir, studied in the Phase2 trial, has cleared any detectable levels of cytomegalovirus…
European Commission (EC) has granted Marketing Authorization of ONIVYDE, also known as nal-IRI or MM-398, for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy.
Drugmaker Shire Plc clinched its six-month pursuit of Baxalta International Inc on Monday with an agreed $32 billion (22 billion pound) cash and stock offer, catapulting it to a leading position in treating rare diseases.
“We were disappointed, but will soon have data from the Phase 3 study, OPUS 3,” said Flemming Ornskov, M.D., CEO, Shire.